Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046354 | 1.00 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL13322066 | 0.74 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4051900 | 0.73 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL4052390 | 0.73 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7144408 | 0.70 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL7146688 | 0.70 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7145305 | 0.68 | ADORA2A (0.63) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7151666 | 0.67 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL9435084 | 0.67 | ATM (0.42) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7146839 | 0.66 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | ADORA2A 2/4885ADORA1 12/4885ADORA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.